PubMed

Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.

Swanton C, Szallasi Z, Brenton JD, Downward J.

Breast Cancer Res. 2008;10(5):214. Epub 2008 Oct 31. Review.PMID: 18986507 [PubMed - indexed for MEDLINE]Related articlesFree article

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.

Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM.

Breast Cancer Res. 2009;11(4):R55. Epub 2009 Jul 28.PMID: 19638211 [PubMed - indexed for MEDLINE]Related articlesFree article

cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.

Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM.

Breast Cancer Res Treat. 2006 Mar;96(1):17-39. Epub 2005 Dec 2.PMID: 16322897 [PubMed - indexed for MEDLINE]Related articles

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

Cancer Cell. 2007 Oct;12(4):395-402.PMID: 17936563 [PubMed - indexed for MEDLINE]Related articles

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2008 Apr 2;299(13):1574-87.PMID: 18387932 [PubMed - indexed for MEDLINE]Related articlesFree article

A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.

Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L.

Breast Cancer Res Treat. 2009 Aug;116(3):509-20. Epub 2008 Nov 20.PMID: 19020972 [PubMed - indexed for MEDLINE]Related articles

Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

Györffy B, Serra V, Jürchott K, Abdul-Ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schäfer R.

Oncogene. 2005 Nov 17;24(51):7542-51.PMID: 16044152 [PubMed - indexed for MEDLINE]Related articles

Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer.

Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, Bajetta E, Celio L, Greco M, Fabbri A, Pierotti MA, Daidone MG.

Endocr Relat Cancer. 2008 Jun;15(2):439-49.PMID: 18508997 [PubMed - indexed for MEDLINE]Related articlesFree article

Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.

Paik S.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1019s-1023s.PMID: 16467119 [PubMed - indexed for MEDLINE]Related articlesFree article

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G.

Breast Cancer Res. 2008;10(5):R81. Epub 2008 Sep 29.PMID: 18823530 [PubMed - indexed for MEDLINE]Related articlesFree article

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, Toy K, Rivers CS, Modrusan Z, Amler LC, Lackner MR.

Cancer Res. 2008 Jul 1;68(13):5380-9.PMID: 18593940 [PubMed - indexed for MEDLINE]Related articlesFree article

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.

van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC.

Br J Cancer. 2009 Dec 1;101(11):1824-32. Epub 2009 Nov 10.PMID: 19904269 [PubMed - indexed for MEDLINE]Related articles

PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?

Park BH, Davidson NE.

Cancer Cell. 2007 Oct;12(4):297-9.PMID: 17936554 [PubMed - indexed for MEDLINE]Related articles

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Herschkowitz JI, He X, Fan C, Perou CM.

Breast Cancer Res. 2008;10(5):R75. Epub 2008 Sep 9.PMID: 18782450 [PubMed - indexed for MEDLINE]Related articlesFree article

Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.

Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH.

Cell Biochem Biophys. 2009;55(2):95-105. Epub 2009 Jul 11.PMID: 19593673 [PubMed - indexed for MEDLINE]Related articles

Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.

Rennstam K, Jönsson G, Tanner M, Bendahl PO, Staaf J, Kapanen AI, Karhu R, Baldetorp B, Borg A, Isola J.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):95-106.PMID: 17213017 [PubMed - indexed for MEDLINE]Related articles

Genomic grade index is associated with response to chemotherapy in patients with breast cancer.

Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L.

J Clin Oncol. 2009 Jul 1;27(19):3185-91. Epub 2009 Apr 13.PMID: 19364972 [PubMed - indexed for MEDLINE]Related articles

Genomic testing for sensitivity of breast cancer to hormonal therapy.

Symmans WF.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1954-5. No abstract available. PMID: 16609001 [PubMed - indexed for MEDLINE]Related articlesFree article

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. Epub 2009 Jan 5.PMID: 19123925 [PubMed - indexed for MEDLINE]Related articlesFree article

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W.

Cancer Res. 2009 Jul 15;69(14):5820-8. Epub 2009 Jul 7.PMID: 19584296 [PubMed - indexed for MEDLINE]Related articles